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SUMMARY OF THE THESIS 
 
Sepsis has become a major health economic issue, with more patients dying in hospitals due to 
sepsis related complications compared to breast and colorectal cancer together. Despite extensive 
research in order to improve outcome in sepsis over the last few decades, results of large multicenter 
studies were by-and-large very disappointing. This fiasco can be explained by several factors, but one of 
the most important reasons is the uncertain definition of sepsis resulting in very heterogeneous patient 
populations, and the lack of understanding of pathophysiology, which is mainly based on the imbalance 
in the host-immune response. However, this heroic research work has not been in vain. Putting the 
results of positive and negative studies into context, we can now approach sepsis in a different concept, 
which may lead us to new perspectives in diagnostics and treatment. While decision making based on 
conventional sepsis definitions can inevitably lead to false judgment due to the heterogeneity of patients, 
new concepts based on currently gained knowledge in immunology may help to tailor assessment and 
treatment of these patients to their actual needs. 
Early diagnosis of sepsis is crucial in treating septic patients and in these cases starting appropriate 
antibiotic therapy in time have a significant effect on survival. However, there is very little to help the 
clinician during the first 24 hours whether the administered empirical antibiotics treatment is effective or 
not. Procalcitonin is a reliable sepsis marker with short half life but its role in predicting bacterial 
infection and early decision making in assisting antibiotic therapy is undiscovered. 
Therefore we investigated the value of procalcitonin levels and changes from the day before (t
-1) to 
the day when infection was suspected (t0), and after starting empirical antibiotic therapy 8 hourly (t8, t16, 
t24) then daily (day2-5) in predicting infection and if the antibiotic treatment is effective or ineffective in 
intensive care patients. 
Our results showed significant difference in procalcitonin kinetics in patients with and without 
bacterial infection and whom empiric antibiotic treatment is turned out afterwards to be effective or 
ineffective. 
There are three fundamental questions to be answered when treating patients with suspected or 
proven infections on the ICU: 1) is there infection, in other words should we start empirical antibiotic 
therapy; 2) is the commenced antibiotic effective; and finally 3) when should we stop antibiotic 
treatment? Our research team decided to give exact answers to these questions with the help of 
procalcitonin as it is a fundamental problem in our daily practice in the ICU.  
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1 INTRODUCTION 
 
One of the most challenging tasks in critical care medicine is the treatment of serious infection 
related multiple organ dysfunction, termed in general as sepsis, severe sepsis, and septic shock. Despite 
improved awareness of critical care practitioners and the implementation of international guidelines, the 
mortality ranges between 28-41% in North America and Europe alike and still the leading cause of 
death among critically ill patients worldwide [1]. However, sepsis means a very heterogeneous patient 
population, which varies in etiology and severity; therefore, universally applicable diagnostic criteria 
and treatment algorhythms are difficult to be defined. This heterogeneity proved to be one of the most 
difficult hurdles that most prospective randomized trials could not concur; hence, they failed to show 
either clear survival benefit or positive results of single center studies that were later contradicted by 
large multicenter trials [2]. Nevertheless, sepsis has become a very important health economic issue all 
around the world. 
Furthermore, treating sepsis is a multidisciplinary task. Early recognition and immediate start of 
initial steps which stand on three main pillars of: resuscitation parallel with source control and adequate 
antimicrobial therapy [3] undoubtedly are inevitable to give the best possible chance for survival 
received strong recommendation by the Surviving Sepsis Campaign guidelines [1], which has to be 
started on the primary care level: outside the hospital, in the emergency department or on the wards. In 
the absence of adequate initial management, providing even the highest level of intensive care would be 
in vain (Figure 1). There is firm evidence that delaying appropriate antibiotic treatment increases 
mortality regardless from the severity of organ dysfunction [4, 5]. 
However, in almost 30% of cases empirical antibiotics proved to be inadequate in the hospitals in 
general and on intensive care units (ICU) as well [6]. To improve efficacy, empirical antibiotic therapy 
is guided by local protocols based on international guidelines in most centers. 
However, while recognizing organ failure via objective signs is relatively easy, diagnosing 
infection as possible underlying cause remains a challenge. Due to the non-specific properties of 
conventional signs of infection, such as body temperature and white blood cell count (WBC), 
biomarkers have been searched to aid diagnosis for decades. 
One of the most studied biomarkers is procalcitonin (PCT) [7]. Its role in assisting antibiotic 
therapy has been studied extensively, with contradicting results. There are positive studies [8, 9] 
showing that a PCT-guided patient management reduced antibiotic exposure and length of antibiotic 
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therapy without affecting patient outcomes. There are also negative studies, which could not show this 
benefit at all [10–12]. 
 
 
Figure 1 “Sepsis-triangle” treatment. EC - extra corporeal and IPPV - intermittent positive 
pressure ventilation 
 
Although the results of prospective randomized clinical trials may be disappointing as far as 
survival is concerned, it is beyond doubt that we have learned a lot about the pathophysiology of sepsis 
during performing these studies over the last few decades understanding the values and limitations of 
inflammatory biomarkers it is inevitable to understand the immunological background of critical illness 
determined mainly by the host response. Moreover, putting the results of these studies in the context, 
based on new insights of the pathomechanism of the clinical picture of sepsis and systemic 
inflammation generated mainly by the individuals’ host response, may explain the differences between 
the reported results and help the clinician to interpret results of diagnostic tests and rationalize treatment 
modalities with more confidence in the most appropriate way at the bedside. 
1.1 Sepsis is not a “definitive” disease 
In medical school we were brought up in the world of “definitive diagnoses.” This means that 
patients come in with a certain complaint, the physician after taking medical history, performing 
physical examination and diagnostic tests, defines the diagnosis and treat the patient accordingly. In the 
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case of a well-defined disease more-or-less the same or similar diagnostic tests and therapeutic 
interventions are performed all around the world. This holds true for most diseases in classical medicine 
and surgery as examples, in stroke, myocardial infarction, bone fractures, intracranial haemorrhage, 
etc., we have diagnostic tests with very high sensitivity and specificity. However, defining sepsis is not 
that simple. 
The term we call “sepsis syndrome” was conceived in a hotel room in Las Vegas in 1980, during 
the designing of the protocol writing of one of the first prospective randomized trials in sepsis, 
performed by a group of scientists led by the late Roger Bone [13]. The study ended with non-
significant results, but based on the inclusion criteria of this study a statement paper was later published 
by the same authors titled “Sepsis Syndrome: A Valid Clinical Entity” [14], after which the medical 
society started to deal with sepsis as with a definitive disease. As a definitive disease, physicians 
wanted one single test with high sensitivity and specificity to diagnose sepsis, and there was an urge to 
find an “anti-sepsis magic bullet”. Neither of these wishes have and will never ever come true. 
Regarding the definition and diagnosis of sepsis, the classical signs of the “sepsis syndrome” such 
as fever/hypothermia, leukocytosis/leukopenia, tachycardia and hypotension, meant a very large and 
non-specific/non-infectious cohort of patients. For this reason, a few years later a consensus conference 
was brought together and defined the so called “consensus criteria” of sepsis which has been used for 
decades in research and clinical practice alike [15]. In the most current SSCG a more robust, more 
detailed definition has been created, in order to “save” the previous concept of the Bone criteria [1] but 
it has almost immediately been questioned and criticized by experts, also taking part in the Surviving 
Sepsis Campaign process [16]. 
These efforts clearly show that finding the appropriate definition of sepsis has been a continuous 
challenge for more than 30 years. The difficulty in defining sepsis originates from its pathophysiology, 
which is affected by numerous individual variations of the host response. This has been recognized by 
international societies and currently an international Task Force has been working on a new, 
pathophysiology based sepsis definition. Nevertheless, in most specialties diagnostic laboratory or 
radiological tests have very high sensitivity and specificity often reaching almost 95-100% [17]. 
However, in the case of sepsis it is different, which makes not just the diagnosis but the interpretation of 
the results of clinical trials and also epidemiological data very difficult. 
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1.2 Epidemiology 
According to recent surveys we treat several folds more critically ill patients on the intensive care 
units worldwide these days as compared to the figures from more than 10 years ago [18]. There seems 
to be an increase in the incidence of sepsis, with mortality rates of 20–50%, and according to recent 
data from the United States, sepsis is the single most expensive reason for hospitalization at present [19, 
20]. However, it is important to note that reported mortality shows considerable variation across the 
globe. A recent retrospective analysis from Australia and New Zeeland showed an increase in the 
number of critically ill and septic patients over the last 12 years, with a mortality reduction from more 
than 30% to less than 20% [18]. In the PROCESS trial from the United States mortality was around 
20% [21]. According to these data outcome has improved dramatically over the years. However, results 
from Europe, both retrospective and prospective, indicate greater mortality of 45–55%, which was also 
accompanied by a 2- to 3-fold longer ICU and hospital stay [22, 23], as compared to that reported by 
the two previously mentioned studies. This raises the question of whether the care is better in those 
countries which reported lower mortality rate or is it the patient selection that causes this difference? 
Although it is difficult to give a definitive answer, referring to our previous chapter, due to the 
difficulties in defining sepsis, severe sepsis, and septic shock, one cannot exclude that this difference 
can be the result of the uncertainties in patient selection, and, in those countries reporting higher 
mortality rates, sicker patients were included in the “septic shock” cohort. 
Indeed, patients with the same diagnosis of “septic shock” could have completely different severity 
and prognosis. The same holds true for every potential “insult” in critical care, such as trauma, sterile 
inflammation (acute pancreatitis), ischemia-reperfusion injury, major surgery, burns, and infection. 
These conditions share the same feature in their pathophysiology, namely, that it is not the insult per se, 
but the host’s response, especially the immune response, which determines severity and outcome 
(Figure 2). 
1.3 Pathophysiology 
1.3.1 From Localized Insult to dysregulated host response caused Cytokine Storm 
The immune system is a complex network that involves many different players interacting with 
each other as an orchestra, a dynamic balance between the pro-, and anti-inflammatory forces. The 
immune response to pathogens relies on both innate and adaptive components. The first line of defense 
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against invaders consists of physical barriers such as the skin [24, 25], the mucous membranes of our 
gastrointestinal [26], and respiratory [27] and genitourinary [28] tracts. The second line is the rapid 
defense, eradication of the invaders by the innate immune system (including complement proteins, 
sentinel phagocyte cells, and natural killer cells), which plays an activator and a controller role of the 
adaptive immune system [29]. The innate system acts by broad recognition of antigens, mainly by 
sensing pathogen-associated molecular patterns (PAMP) of carbohydrates and fatty acids located on the 
surfaces of common pathogens. While the adaptive immune system’s role is to control the process and 
keep it localized to the site of the insult [30]. By-and-large when there is an imbalance due to the 
dysregulation of the pro-, and anti-inflammatory forces, the local response spread systemically the 
activation of several classes of pattern recognition receptors will generate a “cytokine-chemokine 
storm” [31, 32].  
 
 
 
Figure 2 “Sepsis-triangle”: pathomechanism. SIRS - systemic inflammatory response 
syndrome; I-R - ischemia-reperfusion; DO2 - oxygen delivery; VO2 - oxygen consumption; 
PAMP - pathogen-associated molecular patterns; DAMP - damage-associated molecular 
patterns 
 
However, very similar molecules are released due to cell injury after trauma, burns, ischemia-
reperfusion, pancreatitis, major surgery, and so forth, derived mainly from the mitochondria of the 
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injured or stressed cells that found during PAMPs, and can also cause a cytokine storm. This process 
accompanying tissue injury is called “damage-associated molecular patterns” (DAMP).This similarity 
is due to the fact that the bacteria and the mitochondria (which is more-or-less an encapsulated 
bacterium) share very similar genetic background. This explains why tissue injury induced DAMP and 
bacterial infection induced PAMP manifest in similar host responses and clinical manifestations [33]. 
This highlights the fact that the Bone-concept inevitably mixed patients who suffered insults due to 
PAMP, DAMP or the mixture of the two. 
Activation of neutrophils, macrophages, and monocytes by costimulatory molecules at the site of 
infection will turn the local adaptive immune system on and give “permission” to the adaptive system to 
respond to an infectious insult. The aim of the innate response is the eradication of the DAMP and 
PAMP, which is followed by the adaptive response with the resolution of the immunological process. 
The adaptive immune response is based on maturation and proliferation, both influenced by the 
“cytokine signature” of the innate response. In other words, every host has its own “cytokine signature” 
for a certain insult. Under normal circumstances these processes are well regulated maintaining an even 
balance between counteracting forces, hence keeping the inflammatory response localized. 
However, in the case of an unbalanced (pro-inflammatory and anti-inflammatory), dysregulated 
(maturation and proliferation) response, the localized process goes out of control and becomes 
systemic, in other words the disease of the whole body; hence, it gives way for impairing the function 
of distant vital organs. This makes the clinical manifestation of critical illness so similar regardless of 
the insult. To give an example, the same gravity of acute respiratory distress syndrome (ARDS), shock, 
or deterioration in mental function can occur in pancreatitis, just as well as after major surgery, or due 
to any type of infection (Figure 3). The adaptive immune system as the third level of defense is based 
on its memories. It can adapt and protect us against almost any invader. 
In brief the “cytokine signature” of neutrophils and macrophages will give signals to the T and B 
lymphocytes via the dendritic cells, which after proliferation by maturation will express different cell 
surface receptors in soluble ormembrane bound forms. The adaptive immune response is a soluble 
matrix, which consists of the cascade-type activation of cytokines, coagulation factors, the release of 
acute phase proteins, stress hormones, and different chemokines and hormokines, forming a complex 
network. The key factor of immune resolution is the balance between pro-inflammatory and anti-
inflammatory forces, which is mainly determined by the balance between the relationship of Th1, Th2, 
Th17, and ∆T to each other, namely, the maturation, magnitude, and the duration of their activity [34]. 
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Figure 3 The main pillars of systemic inflammatory response. PAMPs - pathogen-
associated molecular patterns; DAMPs - damage-associated molecular patterns; MBL - 
mannose-binding lectin; NOD protein - nucleotide-binding oligomerization domain protein; 
and NALP - a type a NOD like receptor 
1.3.2 From Systemic Inflammatory Response Syndrome (SIRS) to dysregulated host response and 
Immunoparalysis 
Based on the Bone-criteria, systemic inflammatory response syndrome, invented on the Consensus 
Conference in 1991 [15], initially meant the classical “sepsis syndrome” criteria, without proven 
infection. The SIRS-criteria have also been criticized for similar reasons as the “sepsis syndrome” 
definition, but nevertheless this “SIRS concept” assumed that systemic inflammatory response can 
occur for an insult without infection. 
In the past SIRS was mainly thought to be related to the imbalance between the pro-inflammatory 
and anti-inflammatory responses. However, it is more complex. In the context of the innate and 
adaptive immune responses both pro-inflammatory and anti-inflammatory processes take place in a 
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parallel fashion. Normally, an infectious insult is followed by the activation of both the pro-, and anti-
inflammatory forces. In general we can say that there is a short delay of the anti-inflammatory response 
as compared to the pro-inflammatory. Nevertheless, the role of pro-inflammation, mainly regulated by 
the innate immune system, is to kill the invaders, while the adaptive immune system regulated anti-
inflammation’s task is to keep the process localised, and apart from general symptoms as being weak, 
suffering from fever, there is no other harm done, and after a few days the fight against the pathogens is 
over, the immunity return to baseline activity. However, in septic patients an oversized pro-
inflammatory response may take place, via which the localized insult becomes systemic, and will lead 
to different degree of tissue damage, shock, and eventually organ failure [30]. These patients can die 
within hours or days due to this fulminant septic shock. At a later stage a dysregulated, systemic form 
of the adaptive response, which means an overwhelming anti-inflammatory response, could induce 
immunoparalysis, jeopardizing the body’s defense, hence leaving it prone to further, even opportunistic 
infections [32]. These patients usually suffer from recurrent septic insults and may also die due to this 
acquired immune suppression. 
1.4 Diagnostic Challenges 
The question “Is this patient septic?” is frequently asked on intensive care unit ward rounds. 
However, this may be an irrelevant issue. Why? Because on the one hand, we should recognize a 
critically ill patient via objective signs of organ dysfunction such as hypotension, hypoperfusion, altered 
mental status, acid-base imbalance, hypoxemia, lactate levels, renal and liver dysfunction, and 
thrombocytopenia, which renders the immediate start of basic and organ specific supportive therapy, 
regardless of the actual diagnosis. On the other hand, what is of pivotal importance is not that the 
patient is septic or not, but whether the onset of critical illness is due to infection or not? If there is any 
suspicion of the possibility of an infection, after the fist level of resuscitation, empirical antibiotic 
therapy should be started immediately and also other levels should be performed of the sepsis triangle 
like surgical source control (Figure 1) [27]. But if it is not related to a bacterial infection, antibiotics are 
not just a waste of time and money, but they may also do harm in short and long term, due to its several 
undesired effects. Therefore, it is not “sepsis” what we treat, but organ dysfunction and infection. 
Diagnosing infection on the ICU is not easy and requires a multimodal approach. One of the most 
common misconceptions in sepsis diagnosis is that we have been searching for specific “marker(s) of 
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sepsis.” However, there is not and there will never be one single marker which is able to diagnose 
sepsis, mainly due to the very colourful manifestation of sepsis and due to the heterogeneity of patients. 
1.4.1 Conventional Markers of Infection 
Clinical signs are the most important in recognizing critical illness and suspecting infection and 
even the source of infection, but they cannot prove infection on their own. Conventional 
(fever/hypothermia, leukocytosis/leukopenia, tachypnoe, tachycardia and hypotension) indicators, also 
listed in the classical “sepsis-syndrome” criteria, are very nonspecific, in fact poor indicators of 
infection [35]. For microbiological proof of infection, although the gold standard of the diagnosis, 
unfortunately results often only become available 24–48 hours at the earliest after sending the specimen 
to the laboratory, and negative result do not necessarily rule out infection. According to our current 
concept, it is of utmost importance to start adequate antibiotic therapy as soon as possible, but at least 
within an hour after the onset of infection caused hypotension; otherwise chances for survival are 
reducing by the hour [4]. 
Neutrophil-lymphocyte count ratio is a cheap, fast, and easily available tool to diagnose bacteremia 
and was found to improve bloodstream infection diagnostics in a recent study on the emergency ward 
[36]. This simple test may also have a potential in the future. 
Finally, new molecular biology techniques are now available to define the presence of bacterial or 
fungal DNA within the bloodstream of patients [37, 38]. Highly sophisticated molecular biology based 
tests such as polymerase chain reaction (PCR), matrix assisted laser desorption/ionization (Maldi/Tof), 
and peptide nucleic acid fluorescence in situ hybridization (PNAFISH) based pathogen detection can 
theoretically shorten the recognition of the underlying pathogen to about 8 hours [39]. However, these 
cannot differentiate between colonization and clinically significant infection. To fill this gap 
inflammation indicator laboratory measurements have been developed, which are sensitive and specific 
enough to show the onset and magnitude of bacterial invasion caused inflammatory response as soon as 
possible and may also be able to follow the progress of the disease within hours. These biologically 
active substances are called biomarkers. 
1.4.2 The Role of Biomarkers at the Bedside 
There have been several biomarkers developed so far [2], but neither is suitable for all purposes. 
Every marker has its own merit and limitations. They inevitably can support decision making but they 
will never be able to differentiate “sepsis” from “SIRS” with a100% sensitivity and specificity, mainly 
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due to the problems we discussed earlier in details regarding the problems of defining sepsis, and also 
due to the complex, overlapping pathomechanism of PAMP and DAMP. This is in sharp contrast with 
the diagnostic power of certain biomarkers used in the world of “definitive” diseases, where several 
laboratory parameters have this ability. Nevertheless, there is still an ongoing search for better, new 
markers of inflammatory response and infection, with promising preliminary results [40]. 
There are almost 200 so-called sepsis markers [7]; therefore, discussing the features of those cannot 
be integrated into my current thesis. I will mainly focus on the two most commonly used markers in 
infection/sepsis diagnostics and for guiding therapeutic interventions: procalcitonin (PCT) and C-
reactive protein (CRP) [7]. However, briefly mentioning the main features of a few of other new 
markers already applied in daily practice, such as soluble CD14 subtype (presepsin) and soluble 
urokinase-type plasminogen activator receptor (suPAR), maybe worthwhile. Higher presepsin 
concentrations in septic patients were associated with ICU mortality in a recent large multicenter trial 
[41]. It was also suggested that changes in plasma concentrations may reflect the appropriateness of 
antibiotic therapy, but this have to be confirmed by future studies [41]. Regarding the suPAR molecule 
it has been shown to be a very good indicator of severity of the acute disease and shows good 
correlation with the degree of organ dysfunction in the critically ill but cannot be regarded as a “sepsis 
marker” due to its low specificity [42]. 
Any condition inducing DAMP [43] or PAMP could shed the endothelial glycocalyx layer. It has 
been confirmed in several experimental studies in different septic models that damage of the endothelial 
glycocalyx layer is reflected in elevated serum syndecan-1 and syndecan-4 levels [44–47] which may 
be potentially a very interesting marker in the future, but again, it may be nonspecific for bacterial 
infection only. 
Nevertheless, the two most commonly used markers in infection/sepsis diagnostics and for guiding 
therapeutic interventions are PCT and CRP [7]. Despite their popularity, there are still many pros and 
cons without clear answers regarding their usefulness and interpretation in guiding patient management. 
Procalcitonin is detectable in the serum within a few (4–6) hours after the onset of bacterial 
infection. During the “normal” course of an infection it reaches its peak within 24 hours and then starts 
its decline in the case of adequate treatment with levels reducing by roughly 50% daily according to its 
half-life [48]. In contrast, CRP moves “slowly”, and under similar circumstances it reaches its 
maximum value usually within 48 hours. This is in general unacceptable on the ICU, as every hour 
delay in starting for example appropriate antibiotic treatment can affect mortality as indicated by the 
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study of Kumar et al. [4]. However, levels are generally elevated in most ICU patients, making 
interpretation of CRP very difficult [49]. The other major problem with CRP on the ICU is that it is 
lagging way behind the actual events of the inflammatory process. The most important differences 
between the two markers are summarized in Table 1. 
 
Table 1 Comparison of CRP vs. PCT (advantages and disadvantages) 
 CRP PCT 
Differentiating bacterial 
infection from SIRS - specific for bacteria 
Response to infection slower (days) 2-6 hours 
Peak response after infection 2-3 days 12-48 hours 
Half life several days 20-35 hours 
Plasma kinetic slow rapid 
Price + ++++ 
Correlates disease severity, and 
progression slightly +++ 
 
Correlates effective therapy + +++ 
Prognostic factor for mortality weak or nonexistent good predictor 
Differentiating G+ from G- - ++ 
Response to other factors virus, autoimmune diseases, local infections, surgery, trauma 
surgery, trauma, burn, cardiogen 
shock, liver chirrosis 
Fungal infection same as bacterial slightly elevated 
Immunsuppression formation can be changed the induction is reduced 
Biological effect opsonin for phagocytosis chemokine 
Sensitivity/specificity sensitive but nonspecific sensitive and specific 
General use outpatient care intensive care 
 
Procalcitonin differentiates bacterial infections from systemic inflammatory response of other 
etiologies with higher sensitivity and specificity compared to CRP [50] and also have a good prognostic 
value regarding survival [51]. There is considerable evidence that PCT supported decision making 
during antibiotic treatment has several beneficial effects. It considerably reduced antibiotic use in lower 
respiratory tract infections without compromising survival [8], and it may also shorten the duration of 
antibiotic treatment on the ICU [9].There are many studies reporting that PCT values correlate with 
severity and differ significantly in patients with SIRS, sepsis, severe sepsis and septic shock [52].It 
must be considerated that the same absolute values of PCT cannot be used in all circumstances. It has 
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been reported that PCT levels are higher in surgical compared to medical patients [53], and elevated 
PCT can also be present without infection, in conditions such as trauma [54], surgery [55] or after 
cardiac arrest [56]. There is some evidence that evaluating PCT kinetics may be superior to absolute 
values [53, 57]. However, learning how to use biomarkers and interpreting PCT values correctly on 
admission or after the onset of an acute insult, let it be infectious or not, is not simple. 
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2 AIMS AND SCOPES 
 
There are three fundamental questions to be answered during our ward rounds when treating 
patients with suspected or proven infections on the ICU: 1) is there infection, in other words should we 
start empirical antibiotic therapy; 2) is the commenced antibiotic effective; and finally 3) when should 
we stop antibiotic treatment? Our research team decided to give exact answers to these questions as it is 
a fundamental problem in our daily practice in the ICU. 
Starting with the second question, during the initial phase of sepsis treatment before the first 
microbiological results physicians have little help to confirm adequacy of the commenced antibiotics. 
As PCT is a fast reacting biomarker with a half-life of 24 hours, theoretically it is possible that the early 
kinetics of PCT within this first 24 hours after commencing empirical antibiotic therapy may reflect the 
efficacy of the treatment. As this has not been investigated before, we decided to perform a prospective 
observational study with 3 goals: a) to describe early kinetics of PCT measured 8 hourly after starting 
empirical antibiotic therapy within the first 24 hours, b) to investigate if the observed kinetics shows 
any difference in patients in whom the antibiotic treatment eventually proved to be appropriate versus 
those in whom it proved to be inappropriate, and c) to determine the cut-off value of PCT with highest 
discriminatory power. 
Regarding the first question, as a spin off study after the original EProK-study has been completed, 
in a post hoc analysis those patients in whom PCT and CRP values were available from the previous 
day (t
-1) were included in a second analysis. Our aim was to investigate whether the absolute value of 
PCT measured in critically ill patients on the day when infection was suspected, or the change in PCT 
(delta PCT) from the day before to the day when infection was suspected, was a better indicator of 
infection. 
However concerning the third question we found to be answered by Boudama et al. in the 
PRORATA trial [9], as our daily practice is accepted applying that algorithm so our study has not been 
extended for investigating the duration of the antibiotic therapy. 
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3 METHODS 
 
3.1 Patient selection 
This prospective observational study was undertaken between October 2012 and October 2013 
and was approved by the Regional and Institutional Human Medical Biological Research Ethics 
Committee, University of Szeged, Hungary (WHO-3005; 19.04.2012, Chairperson Prof. T. Wittmann). 
The investigation was performed at the University of Szeged (Szeged, Hungary), Albert Szent-Györgyi 
Health Center in a 27 bed multidisciplinary tertiary intensive care unit. The study was registered at 
ClinicalTrials.gov with the registration number: NCT02294695. Written informed consent was 
obtained from all subjects or from their relatives. 
Inclusion criteria: All patients over 18 years with suspected infection on admission or during their 
stay on the intensive care unit were screened for eligibility. Patients were enrolled when the attending 
intensive care specialist suspected infection (for explanation see below) and decided to start empirical 
antibiotic therapy. 
Exclusion criteria: age <18 years; antimicrobial therapy within 48 hours; conditions that have 
been shown to interfere with the inflammatory response such as: acute renal replacement therapy in the 
first 24 hours [9], cardiopulmonary resuscitation[58], patients with end stage diseases and 
immunocompromised patients. 
3.2 Subgroups and definitions 
Diagnosis of infection and appropriateness of the empirical antimicrobials were established as a 
retrospective analysis based on recommendations [58], clinical parameters, biochemical and 
microbiological results, evaluated by two experts blinded for the PCT data apart from the first PCT 
result: an infectologist and an intensivist, who also took into consideration the recommendations of the 
International Sepsis Forum Consensus Conference [58]. Based on these results, patients were then 
grouped into Infectious-, and Noninfectious-groups. Patients with suspected infection but negative 
microbiology were also excluded from the final analysis. 
Antimicrobial therapy was also evaluated, and it was considered appropriate, if a) the isolated 
pathogens were susceptible to at least one of the commenced antimicrobials [59] administered at the 
onset of sepsis according to the corresponding susceptibility testing report, and the appropriate dosage 
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as recommended by our local protocols. Based on these results patients were grouped “post hoc” into 
appropriate (A-group) and inappropriate (IA-group) antimicrobial treatment groups. 
For subgroup analysis, patients were also divided further into ’Medical’ and ’Surgical’ groups. 
Medical-group represents patients, who had no surgical intervention before and during the study 
period, and for source control they did not require surgery. In the Surgical-group infection was either 
related to an operation, or required surgery for source control [60]. These groups were also further 
divided post hoc into appropriate and inappropriate antibiotic groups: Am(edical)-, and As(urgical)-group; 
IAm-, and IAs-group. 
3.3 Protocol and data collection  
Whenever infection was suspected by the attending physician, the signs of infection and the 
suspected source were recorded, which were: high/low temperature (<36°C; >38°C), white blood cell 
count (<4.000; >12.000 million/ml), acute worsening of the clinical picture (hemodynamic instability, 
worsening PaO2/FiO2 ratio, deterioration in mental status or any other clinical sign indicating 
infection) and elevated or increasing (as compared to the previous day) PCT levels. Specimens were 
then sent for microbiology and antibiotic therapy was commenced. The choice of antimicrobials was 
determined by local protocols based on international guidelines [61–63]. 
3.3.1 Data collection 
After enrollment demographic data and parameters of vital organ function were registered. 
Patients were followed up for 6 days. In addition to detailed collection of physiological and laboratory 
data during those 6 days, the length of intensive care unit and hospital stay, 28 day-, and the overall 
mortality were also documented. 
3.3.2 Procalcitonin measurement 
Procalcitonin levels were determined immediately before the initiation of antimicrobials (t0), 8 
hourly (t8, t16, t24) during the first 24 hours and then daily (day2-day6). The flow chart of the data 
collection is summarized in Figure 4. 
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Figure 4 Flowchart: t0-24 indicates sampling within the first 24 hours after commencement 
of empirical antimicrobials; SAPS II - Simplified Acute Physiology Score II; SOFA - 
Sequential Organ Failure Assessment; LOS - length of stay 
 
Serum PCT levels were measured with Cobas 6000 analyzer (Hitachi High-Technologies 
Corporation, Tokyo, Japan). Analyzer reagents (Elecsys® B·R·A·H·M·S PCT assay) were developed in 
collaboration with B·R·A·H·M·S corporation (Hennigsdorf, Germany) and Roche Diagnostics 
(Mannheim, Germany). Procalcitonin was determined by electrochemiluminescence immunoassay 
(ECLIA) serum on the automated Roche Elecsys and Cobas immunoassay analyzers. 
3.3.3 Microbiological staining and antibiograms 
Microbiological tests were performed and sent at t0, before the first antimicrobial dose was 
administered and if necessary repeated on the following days, to identify microorganisms and their 
resistance. The type of antimicrobials, the dosage, the bacterial strains and their antibiogram profile 
were recorded daily or whenever the results were available. 
3.4 Statistical analysis 
The primary end point of the study was the difference in PCT kinetics after 24 hours of starting the 
antimicrobial treatment. According to our former pilot study [64] a PCT increase of <70% within the 
first 24 hours, compared to the baseline value (t0) had an 84% positive predictive value with 80% 
sensitivity and 41% specificity (p=0.059), indicating appropriate antimicrobial treatment. Therefore, for 
the study to have 80% power to show the smallest clinically relevant difference of 15% , an increase of 
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PCT between the A-, and IA-groups (i.e.: 70% increase in the IA-, and 55% increase of PCT in the A-
group from t0 to t24) with a p<0.05, the required sample size was at least 161 patients. Based on this 
calculation we decided to enroll patients for at least 12 months. 
Data were analyzed using IBM SPSS Statistics Version 20 (Armonk, NY, USA) and 
SystatSoftware IncSigmaPlot 12.5 (London, UK) software. For continuous data, the Shapiro-Wilk tests 
were performed to assess normal distribution. Demographic data were analyzed between groups with 
the Student’s t-test or non-parametric data with the Mann–Whitney U-test as appropriate. Biomarkers 
were analyzed by using Two Way Repeated Measures Analysis of Variances (All Pairwise Multiple 
Comparison Procedures: Holm-Sidak method). Categorical data were compared using χ2 tests. Receiver 
operating characteristic (ROC) curve and the respective areas under the curves (AUC) were calculated 
for PCT and CRP levels. The best cut off values were determined to maximize the Youden index (J = 
max [Sens + Spec – 1]. The test parameters (sensitivity, specificity, positive and negative predictive 
values) were compared by their 95% confidence intervals. A level of p <0.05 was defined as 
statistically significant. Data are given in mean ± standard deviation or median (25-75% interquartile 
range) as appropriate. 
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4 RESULTS 
 
Over the study period 209 patients were enrolled. Demographics are summarized in Table 2. From 
the 209 patients, 141 (67%) had proven infection, with infection unproven in 44 (21%). In 24 patients,  
 
Table 2 Demographics and infection sources in the entire cohort 
 Total 
(n=209) 
Appropriate AB 
(n=108) 
Inappropriate AB 
(n=33) p value 
Age (years) 68 (19) 68 (19) 69 (20) 0.842 
Male, n (%) 117 (56) 60 (55) 16 (48) 0.476 
Body height (cm) 170 (12) 169 (14) 165 (19) 0.422 
Body weight (kg) 76 (25) 70 (18) 80 (27) 0.218 
SAPS II points 67 ± 19  68 ± 19 72 ± 16 0.333 
SAPS II PM 78 (47) 81 (32) 88 (27) 0.298 
SOFA score points at t0 14 (5) 14 (4) 15 (6) 0.298 
delta SOFA score points (t0-t24) 0 (2) 0 (2) 0 (2) 0.568 
ICU days before enrollment 1(2) 0 (2) 1 (2) 0.798 
ICU LOS (day) 8 (9) 8 (10) 9 (11) 0.263 
ICU survival, n (%) 151 (72) 84 (78) 14 (42) <0.001 
Hospital LOS (day) 15 (17) 16 (22) 17 (16) 0.444 
Hospital survival (%) 126 (60) 68 (63) 13 (39) 0.017 
Mechanical ventilation (day) 4 (8) 4 (9) 7 (8) 0.011 
Vasopressor therapy (day) 3 (4) 3 (3) 5 (4) 0.004 
Renal replacement therapy, n (%) 65 (31) 33 (31) 19 (57) 0.005 
Nosocomial infecion, n (%)  53 (49) 16 (48) 0.953 
Source of infection, n (%) Respiratory  54 (50) 25 (76) 0.007 
 Abdominal  19 (18) 5 (15) 0.744 
 Soft tissue  15 (14) 2 (6) 0.227 
 UTI  10 (9) 2 (6) 0.564 
 BSI  7 (6) 0 0.134 
 Meningitis  5 (5) 0 0.208 
 Other  1 (1) 1 (3) 0.371 
Data are given as median (interquartile range) or mean ± standard deviation as appropriate. 
Total = infection (appropriate and inappropriate) + no infection group; Regarding the source 
of a patient may have more than one infections at the same time. AB - antimicrobial therapy; 
n – number of patients; M - male; SAPS - Simplified Acute Physiology Score; PM - 
predicted mortality; ICU - intensive care unit; LOS - length of stay; UTI - urinary tract 
infection; BSI - bloodstream infection. 
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although infection was highly likely, microbiology did not reveal pathogens, hence these subjects were 
excluded from the final analysis. Procalcitonin at t0 was significantly higher in the Infectious-group 
compared to Noninfectious-group: 4.53 (1.76-16.30) vs. 1.0 (0.13-2.98) ng/ml, p=0.024, respectively. In 
the Infectious-group (n=141) 108 (77%) patients received appropriate antimicrobial therapy (A-group) 
and in 33 (23%) antimicrobials proved to be inappropriate (IA-group). 
Regarding demographics there were no differences between the A-, and IA-groups but ICU-, and 
hospital-survival was significantly higher in the A-group (Table 2). These patients also required less 
vasopressors and renal replacement therapy compared to the IA-group. From the 33 patients in the IA-
group, antimicrobials were changed in 20 patients on day 2 or 3, without any significant effect on PCT 
kinetics, compared to the other 18 patients (data not shown). 
4.1 Procalcitonin kinetics 
In both groups the increase in PCT levels continued after the initiation of empirical antimicrobial 
treatment (t0) until 16 hours (t16) (Figure 5-A). In the IA-group there was a significant increase from t16 
to t24, while in the A-group there was a significant decrease from t16 to t24. By t24 the PCT reached 
significantly higher levels in the IA-group and remained higher the following day compared to the A-
group. In the A-group PCT levels peaked at t16, while in the IA-group the peak was at t24. From t24 until 
the 5th day PCT levels decreased in both groups (Figure 5-A). 
 
 
Figure 5 PCT absolute values in the entire cohort and in the medical and surgical cohort. 
Data are presented as median and interquartile range. AB indicates antimicrobial therapy. 
#p< .05 within groups; * p< 0.05 between groups. 
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There was a non-significant increase in CRP from t0 to t24 in both groups. In the A-group CRP 
peaked at t24. , In the IA-group CRP remained high on day2 with levels remaining higher compared to 
the A-group on days3-5. After day2 CRP levels decreased in both groups (Figure 6-A). Body temperature 
showed no significant change over time (Figure 6-B). 
 
 
Figure 6 CRP and body temperature in the entire cohort 
Data are presented as mean ±standard deviation; AB – antimicrobial therapy; t0-24 - sampling 
within the first 24 hours after commencement of empirical antimicrobials; # p<0.05 within 
groups; * p<0.05 between groups 
4.2 PCT kinetics in medical and surgical patients 
In patients with infection, PCT followed similar kinetics in medical (n=91) and surgical (n=50) 
patients, with substantial differences in the absolute values at t0 (median: 2.74 [25-75% interquartile 
range: 1.30-7.72] vs. 6.46 [2.61-40.07], p=0.002) and at t24 (4.41 [1.52-13.55] vs. 17.02 [6.74-69.45] 
ng/ml, p<0.001, respectively). Medical and surgical patients were further divided into appropriate: Am-
(n=70), As-(n=38), and inappropriate: IAm-(n=21), IAs-(n=12) subgroups. Kinetics in all subgroups 
followed the same pattern as described for the whole sample (Figure 5-B, C). 
Kinetics of CRP where similar in both groups, with no significant differences within and between 
groups during the study period (Figure 7-A, B). The same holds true for body temperature, with the 
only difference being that in the medical cohort at t24, temperature was higher for the next 3 days 
(Figure 7-C, D). 
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Figure 7 CRP and body temperature in medical and surgical patients 
Data are presented as mean ±standard deviation; AB – antimicrobial therapy; t0-24 - sampling 
within the first 24 hours after commencement of empirical antimicrobials; * p<0.05 between 
groups 
4.3 Predictive value of PCT for indicating appropriate antimicrobial treatment 
The ROC analysis revealed that a PCT elevation from t0 to t16 had an AUC of 0.73 (95% CI, 0.63-
0.83; p<0.001), from t0 to t24 0.86 (95% CI, 0.77-0.94; p<0.001) (Figure 8). According to the Youden-
index, the best cut off for PCT increase from t0 to t16 was 69.2%, and from t0 to t24 it was 73.5% (Table 
3). 
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Figure 8 ROC curve 
ROC - receiver operating characteristic curve; PCT – proalcitonin; t0-24 - sampling within the 
first 24 hours after commencement of empirical antimicrobials; AUC - area under the ROC 
curve; CI - confidence interval 
 
Table 3 Cut off values for appropriate and inappropriate antimicrobial treatment in the 
entire cohort 
 
Cut off 
value 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) p 
PCT t0-t8 ≥45.6% 56.5% (0.46-0.66) 
69.7% 
(0.51-0.84) 
31.7% 
(0.28-0.54) 
85.4% 
(0.78-0.92) 0.090 
PCT t0-t16 ≥69.2% 
65.7% 
(0.56-0.74) 
84.8% 
(0.68-0.94) 
42.1% 
(0.33-0.60) 
92.8% 
(0.82-0.95) 0.048 
PCT t0-t24 ≥73.5% 79.6% (0.70-0.86) 
87.8% 
(0.71-0.96) 
53.5% 
(0.41-0.70) 
95.2% 
(0.84-0.98) <0.001 
PCT – procalcitonin; CI – confidence interval; PPV – positive predictive value; NPV – 
negative predictive value; PCT – procalcitonin; The best cut off value was determined using 
the Youden index.  
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5 METHODS OF THE SPIN OFF SUTDY 
 
This prospective observational study, as part of the Early Procalcitonin Kinetics (EProK)-study, 
was registered at ClinicalTrials.gov with the registration number: NCT02311816. 
The analysis was performed from the same database with those patients in whom PCT and CRP 
values were available from the previous day (t
-1), otherwise the inclusion and exclusion criteria were 
the same as in the EProK-study, detailed in the methods chapter earlier. 
5.1 Subgroups and definitions 
Diagnosis of infection was based on a post hoc analysis of mainly microbiological results but also 
clinical parameters and biochemical results which were evaluated by our two experts blinded for the 
PCT data apart from the first PCT measurement (t0, see below). The experts also took into 
consideration the recommendations of international guidelines [15, 58]. Based on these results, 
patients were grouped into ”infection” (I)-, and ”no infection” (NI)-groups. 
For subgroup analysis, patients were divided into ”medical” and ”surgical” groups. The medical-
group represented patients who had had no surgical intervention before and during the study period 
and for source control they did not require surgery. In the surgical-group infection was either related to 
an operation, or required surgery for source control [53]. 
5.2 Protocol and data collection 
The same protocol was followed as described before including the data collection, the PCT 
measurements, the microbiology and the statistical methods too. The flow chart of the data collection 
is summarized in Figure 9. 
 
Figure 9 Flow chart  
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6 RESULTS OF THE SPIN OFF STUDY 
 
Over the one year study period all ICU patients were screened for eligibility and 209 patients were 
recruited into the EProK-study. Out of the 209 patients in the current post hoc analysis we include 114 
cases where PCT values were available from the previous day. Demography and outcomes 
characteristics for the entire cohort are summarized in Table 4. Out of the 114 patients, 85 (75%) 
patients were identified as having proven infection and in 29 (25%) patients the presence of infection 
was highly unlikely. Disease severity scores and outcomes were similar in the two groups, but the NI-
group required less organ support. 
 
Table 4 Demographics, organ support and outcome in the entire cohort 
 Total  NI-group I-group p value 
Age (years) 65 (22.5)  67 (25.5) 65 (22) 0.772 
Gender (M/F) 69/45  15/14 54/31 0.261 
Body height (cm) 170 (12)  167 (19) 170 (11) 0.766 
Body weight (kg) 73 (25)  80 (25) 70 (20) 0.345 
SAPS II points 62.2 ± 20.5  62.7 ± 25.5 66.1 ± 18.6 0.513 
SAPS II PM (%) 77.2 (52.1)  64.0 (75.9) 78.5 (42.1) 0.437 
ICU days before enrollment 1 (3)  1 (3) 1 (3) 0.669 
Mechanical ventilation 80 (70.2%)  12 (41.4%) 68 (80.0%) <0.001 
Vasopressor therapy 69 (60.5%)  13 (44.8%) 56 (65.9%) 0.045 
ICU LOS (day) 9 (12)  8 (8) 9 (12) 0.089 
ICU survival 84 (73.7%)  24 (82.8%) 60 (70.6%) 0.199 
Hospital LOS (day) 17 (20)  14 (17) 19 (22) 0.050 
Hospital survival 67 (58.8%)  20 (68.9%) 47 (55.3%) 0.197 
28 day survival 64 (56.1%)  19 (65.5%) 45 (52.9%) 0.239 
Data are given as mean ± standard deviation or median (interquartile range) as appropriate. 
M - male; F - female; SAPS - Simplified Acute Physiology Score; PM - predicted mortality; 
ICU - intensive care unit; LOS - length of stay; Mechanical ventilation and vasopressor 
therapy represents data at the day of enrollment. 
 
The clinical and laboratory signs of infection on which the clinicians suspected infection at the 
time of inclusion (t0) are summarized in Table 5. Although all indices were higher in the I-group, but 
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only the altered level of consciousness, hemodynamic instability and the PCT was significantly 
different between the two groups. 
 
Table 5 Clinical signs and suspected source of infection at enrollment (t0) 
 
Total 
n=114 
NI-group 
n=29 
I-group 
n=85 
p value 
Fever (<36oC; >38oC) 55 (48.2%) 13 (44.8%) 42 (49.4%) 0.670 
WBC (>12 or<4 x 109/L) 82 (71.9%) 22 (75.9%) 60 (70.6%) 0.585 
Impaired gas exchange 82 (71.9%) 18 (62.1%) 64 (75.3%) 0.171 
Impaired consciousness 59 (51.8%) 9 (31.0%) 50 (58.8%) 0.010 
Hemodynamic instability 74 (64.9%) 13 (44.8%) 61(71.8%) 0.009 
PCT (ng/ml) 3.37 (9.22) 1.12(1.36) 4.62 (10.72) 0.018 
CRP (mg/l) 182.75 (158.5) 147.60(156.50) 208.80(140.60) 0.301 
Respiratory 72 (63.2%) 17 (58.6%) 55 (64.7%) 0.557 
Soft tissue 13 (11.4%) 2 (6.9%) 11 (12.9%) 0.377 
Abdominal 14 (12.3%) 7 (24.1%) 7 (8.2%) 0.024 
Urinary tract 5 (4.4%) 0 5 (5.9%) 0.182 
Bloodstream 6 (5.3%) 2 (6.9%) 4 (4.7%) 0.648 
Central nervous system 4 (3.5%) 1 (3.4%) 3 (3.5%) 0.984 
WBC - white blood cell count, PCT - procalcitonin, CRP - C-reactive protein, The PCT and 
CRP values are presented as: median (interquartile range). 
 
Regarding the suspected source of infection, generally there was non-significant difference 
between the groups, but significantly more patients were suspected of having abdominal related 
infection in the NI-group. 
6.1 PCT, CRP, WBC and temperature values at t
-1 and t0 
6.1.1 Total sample 
Measurement results at t
-1 and t0 in the I-, and NI-groups are shown in Figure 10. PCT absolute 
values were similar at t
-1, but by t0 in the I-group levels were significantly higher compared to the NI-
group and there was also a significant increase from t
-1, while there was no such change in the NI-
group. There was no significant difference in CRP and WBC count between the two groups and nor 
could we find significant changes from t
-1 to t0. There was no difference between the groups for body 
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temperature but there was a statistically significant increase in the NI-group by t0. It is of note that 
body temperature remained <38°C in almost all patients. 
 
 
Figure 10 PCT, CRP, body temperature and WBC count absolute values in the total cohort 
Boxplots presents median (interquartile range) 10th and 90th percentile.* indicates p <0.05 
6.1.2 Medical and surgical patients 
Measurement results in medical (n=80) and surgical (n=34) patients are summarised in Table 6. In 
the surgical subgroup PCT absolute values were significantly higher than in the medical cohort, but the 
pattern of change was similar.  
 
Table 6 PCT, CRP, body temperature and white blood cell count in medical and surgical 
patients with and without infection 
  NI-group I-group 
  t
-1 t0 t-1 t0 
M
ed
ic
al
 PCT (ng/ml) 0.26 (0.57) 0.54 (1.16)* 0.89 (1.52) 3.17 (5.9)*# 
CRP (mg/l) 136.7 (159.1) 141 (125.9) 150 (184.3) 164.2 (145.3) 
BT (°C) 36 (1.02) 37 (0.82)* 36.9 (1.23) 37 (1.6) 
WBC (x109/l) 14.32 (8.9) 15.4 (8.64) 12.06 (6.36) 13.76 (10.16) 
Su
rg
ic
al
 PCT (ng/ml) 3.5 (9.91) 2.89 (9.33) 3.83 (22.55) 14.9 (58.06) *#
CRP (mg/l) 95 (342.5) 163 (327.4) 199.5 (130.1) 243.2 (112.7) 
BT (°C) 36.5 (2) 36.5 (2.4) 36 (1) 36.9 (1.1) 
WBC (x109/l) 8.99 (7.37) 14.56 (9.65) 11.9 (10.06) 10.91 (9.9) 
Data are presented as median (interquartile range).PCT = procalcitonin, CRP = C-reactive 
protein, BT = body temperature, WBC = white blood cell count; * <0.05 within groups, # 
<0.05 between groups 
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In the NI-group there was a slight, but statistically significant increase in medical patients from t
-1 
to t0, while there was no significant change in surgical patients, where levels actually decreased 
slightly. However, in the I-group there was an almost 3-fold increase in the PCT levels. 
Regarding the CRP, body temperature and WBC count, there was no significant changes over time 
and no differences between medical and surgical patients. 
6.2 Predictive value for indicating infection 
The predictive value for infection for the absolute values of PCT, CRP, temperature and WBC 
count can be seen in Figure 11, and are summarised in Table 7. Only PCT had a significant predictive 
value, but with a poor AUC (Figure 11). However, regarding the percentage and delta changes CRP, 
temperature and WBC counts diagnostic value did not change, while PCT’s AUC for both percentage 
and delta changes had a significantly better performance for predicting infection. Similar patterns were 
observed in the medical and surgical subgroups (Table 7). 
 
 
Figure 11 The predictive value of the absolute values, percentage and delta changes of PCT, 
CRP, temperature and WBC count for infection in the total cohort 
6.3 Best cut-off value 
The best cut-off values were defined for PCT only as there was no significant predictive value for 
the other parameters, as determined by the Youden index. For the PCT absolute value it was 
0.84 ng/ml with a sensitivity of 61 % (95% CI: 50-72) and specificity 72 % (53-87) to indicate 
infection in the ICU. Regarding the percentage change a PCT increase of >88% from t
-1 to t0 had a 
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sensitivity of 75% (65-84) and specificity of 79% (60-92) and a PCT delta change of>0.76 ng/ml had a 
sensitivity of 80% (70-88) and specificity of 86% (68-96) to indicate infection. 
 
Table 7 The predictive value of the absolute values, percentage and delta changes of PCT, 
CRP, temperature and WBC count for infection in the total cohort 
 
 
absolute value percentage changes absolute value changes 
 
 
AUC 95% CI p value AUC 95% CI p value AUC 95% CI p value 
To
ta
l 
PCT 0.64 0.52-0.76 0.022 0.77 0.66-0.87 <0.001 0.85 0.78-0.92 <0.001 
CRP 0.60 0.47-0.72 0.103 0.54 0.41-0.66 0.530 0.54 0.42-0.65 0.536 
BT 0.52 0.39-0.63 0.804 0.56 0.44-0.68 0.300 0.56 0.44-0.68 0.322 
WBC 0.60 0.48-0.70 0.125 0.51 0.40-0.61 0.852 0.51 0.39-0.61 0.924 
M
ed
ic
al
 
PCT 0.67 0.54-0.80 0.016 0.76 0.63-0.88 <0.001 0.83 0.73-0.92 <0.001 
CRP 0.58 0.44-0.72 0.248 0.57 0.42-0.70 0.359 0.57 0.44-0.70 0.306 
BT 0.51 0.37-0.64 0.858 0.64 0.50-0.77 0.055 0.64 0.49-0.77 0.060 
WBC 0.57 0.44-0.70 0.329 0.56 0.43-0.68 0.441 0.57 0.43-0.69 0.365 
Su
rg
ic
al
 
PCT 0.78 0.58-0.97 0.025 0.80 0.59-1.00 0.014 0.94 0.85-1.00 <0.001 
CRP 0.56 0.23-0.87 0.654 0.56 0.29-0.81 0.654 0.54 0.31-0.76 0.749 
BT 0.52 0.22-0.80 0.898 0.63 0.39-0.85 0.306 0.63 0.39-0.86 0.296 
WBC 0.63 0.44-0.82 0.277 0.67 0.47-0.86 0.166 0.71 0.49-0.90 0.108 
AUC = area under the ROC curve, CI = confidence interval, PCT = procalcitonin, CRP = C-
reactive protein, BT = body temperature, WBC = white blood cell count 
 
Data were also analyzed using the logistic regression model for finding the best combination of 
these four parameters together to predict infection in the ICU. However, none of the combinations 
tested improved the performance for predicting infection (data not shown). 
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7 DISCUSSION 
 
The main findings of the EProK study were that PCT kinetics during the first 24 hours after 
commencing empirical antimicrobial therapy show significant differences in patients on appropriate 
antimicrobial therapy compared to those on inappropriate antimicrobial therapy and that there were 
significantly higher absolute PCT values, but similar kinetics in surgical compared to medical patients 
with infections. 
7.1 Diagnosing infection 
Despite advances in critical care, diagnosing infection and sepsis has remained a major challenge in 
clinical practice. Appropriate decision making has paramount importance as the delay in adequate 
antibiotic treatment of sepsis and septic shock evokes worsening morbidity and mortality results [4, 58]. 
Although the classical definitions of ’sepsis syndrome’ proposed by Bone et al [14], and the so called 
’consensus criteria’ [15] has been implemented worldwide for decades, it still remains one of the 
greatest challenges to differentiate between systemic inflammatory response from bacterial infection at 
the bedside. It has been shown for long that fever and leucocytosis on their own are poor indicators of 
bacterial infections [35], and the consensus criteria itself has also been criticised [65]. This uncertainty 
in the diagnosis may lead to unnecessary overuse of antibiotics resulting the emergence of multidrug-
resistant bacteria [1, 66], complications related to the side effects of the antibiotics themselves and 
increased burden of healthcare expenses [67, 68]. Despite its importance, there is no gold standard for 
diagnosing/proving infection in the critical care setting. 
In this diagnostic dilemma, there has been considerable interest in the use of infection/sepsis 
biomarkers. Among these biomarkers the two most commonly used are PCT and CRP. Several studies 
have shown that PCT has a better sensitivity and specificity for indicating bacterial infections than CRP 
[69]. This was confirmed by the results from this study, in which as compared to CRP, temperature and 
leukocytosis and where only PCT was able to differentiate patients with proven infection from patients 
with no infection. These results are similar to those reported by recent large randomized trials [8, 9]. 
Procalcitonin is also considered as a good prognostic marker [70] and due to its favourable kinetic 
profile PCT can potentially be a useful biomarker for guiding antibiotic therapy. However, the results 
are so far conflicting. In a landmark study by Christ-Crain et al., antibiotic exposure was reduced by 
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50% (44% versus 83%) with no adverse effect on outcome in patients with acute respiratory complaints 
and receiving antibiotics according to their admission PCT levels as compared to patients treated with 
antibiotics based on conventional signs of infection [8]. A subsequent multicenter trial also found a 
decrease in antibiotic exposure in patients treated on the ICU with community acquired pneumonia by 
32%, exacerbation of COPD by 50% and acute bronchitis by 65% [71]. Similar results were reported in 
another large clinical trial, the PRORATA study [9]. The novelty of the PRORATA study was that not 
only the commencement, but the discontinuation of antibiotic treatment was assisted by PCT levels. 
The results of this study showed that for patients with suspected infections PCT-guided antibiotic 
treatment lowered antibiotic exposure by 23% (14.3 versus 11.6 antibiotic free days) and was non-
inferior to standard care with respect to outcomes. Two German studies assessed the effect of PCT 
guidance in high risk surgical patients with suspected bacterial infections during the postoperative 
period in the ICU [72, 73]. PCT-guided therapy resulted in a significant reduction of antibiotic therapy 
and length of intensive care stay (15.5 versus 17.7 days) with similar other outcomes. Although the 
current study was an observational and not a randomised trial comparing PCT-based therapy to 
conventional measures, but nevertheless our results give further support to the findings above. 
In our spin off study could be seen that an increase in PCT levels from the day before (t
-1) to the 
day when infection was suspected (t0) predicted infection, while in patients with no proven infection 
PCT remained unchanged. Furthermore, regarding the conventional indicators of infection such as 
WBC, body temperature and CRP, neither the absolute values nor their change from t
-1 to t0 could 
predict infection. 
In our study 75% of patients had proven infection. This complex post hoc analysis of all results, is 
fundamentally different from ”labelling” patients as septic, based solely on the Surviving Sepsis 
Guideline criteria at the time of initial assessment most often seen in several studies [74, 75]. Although 
our method also has some uncertainties, but provides a more robust approach with all data - clinical, 
biochemical and microbiology alike -, taken into account to aid the diagnosis of patients with bacterial 
infection. However, it is also important to acknowledge, that there is no gold standard to diagnose 
infection, therefore despite all our efforts, some patients in the NI-group may had culture negative 
infection. 
In our investigation it was found that conventional indicators of infection, such as body 
temperature and white cell count had no value in diagnosing infection. Levels of the WBC count 
remained elevated on both days and there was no significant change in over time. This phenomenon can 
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be explained by the non-specific activation of the immune cascade often seen in ICU patients [12]. 
Although there was a statistically significant increase in body temperature in the NI-group, but levels 
by-and-large remained below 38°C in almost all patients. These results are in accord with recent 
findings that increased temperature alone did not predict infection [76]. 
Although microbiology remains the gold standard for confirming pathogens, but results come back 
late at least 24-48 hours after sampling. Furthermore, in several cases results remain negative, despite 
obvious signs of infection. In order to help the diagnostic process several novel biomarkers of infection 
have been developed [7]. However, all biomarkers share the same limitations that ”one size will not fit 
all”, which is due to the complex pathomechanism and the heterogeneity of patients. 
The two most commonly used markers in infection/sepsis diagnostics are PCT and CRP [7]. 
Procalcitonin is detectable in the serum within a few (2-4) hours after the onset of bacterial infection. It 
reaches its peak within 24 hours and then starts its decline in the case of adequate treatment with 
roughly 50% daily decrease according to its half-life [48]. In contrast, CRP has a delayed response. It 
reaches its maximum value usually after 48 hours of an insult and in general it is lagging way behind 
the actual events of the inflammatory and clinical process. Furthermore, CRP levels are generally 
elevated in most ICU patients regardless of the etiology. In our study neither the absolute values of 
CRP, nor its delta changes could indicate new onset infection. Patients had elevated CRP values with 
median of almost 200 mmol/l for the whole cohort, which makes interpretation very difficult. 
Furthermore the kinetics did not show any significant change over time either. Therefore, our results 
questions the place of CRP measurements for diagnosing infection on the ICU. 
The most important finding of the current study is to show the superiority of PCT kinetics over the 
absolute values to indicate new onset infection on the ICU. These are in accord with that of reported by 
Tsangaris et al. [57]. They observed a two-fold increase of PCT levels from the day before to the day 
when there was a sudden onset of fever in patients with proven infection, but no change in PCT was 
found in patients with no infection. They concluded that in patients treated chronically on the ICU, PCT 
values on the day of fever onset must be compared to values measured on the previous day in order to 
define whether this rise in temperature was due to infection or not. An important difference between 
their and our study is that in our patients, body temperature merely reached 38°C, in fact most of these 
patients were apyrexial, despite 75% had proven infection. Therefore, we recommend to evaluate PCT 
kinetics but not only in the case of fever onset, but whenever infection is suspected on the ICU. Based 
on the current results, the best cut off values were also determined for PCT change, which were >88% 
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and >0.76 ng/ml delta change from t
-1 to t0. The reasons why a given absolute value of any biomarker, 
not just PCT, may be of limited value as compared to its changes can be explained by the 
pathomechanism of systemic inflammation. It was a very important discovery that after trauma, burns, 
ischemia-reperfusion, pancreatitis, major surgery, etc., same or similar molecules are released mainly 
from the mitochondria, as after an infectious insult. Based on etiology these are called ‘damage-
associated molecular patterns’ (DAMP), or ‘pathogen associated molecular patterns’ (PAMP). After 
similar mediators/proteins are released acting on the same receptors of monocytes inflicting similar 
inflammatory response, including PCT release and distant organ dysfunction [33, 77]. 
We observed significant difference in the PCT-levels between patients with and without proven 
infection in contrast to CRP and temperature, suggesting that PCT is superior as a marker for initiating 
antibiotic treatment in the critically ill as compared to CRP and temperature. However, the 
interpretation of PCT measurements, especially the absolute values on their own may be misleading. 
Therefore, evaluating PCT kinetics and an aetiology-based approach may prove more appropriate, 
which will be further discussed in the next paragraphs. 
7.2 Appropriate antimicrobial therapy 
Early identification and adequate antibiotic treatment of septic patients is of pivotal importance as 
any delay in starting effective antibiotic therapy is associated with increased in-hospital mortality [5, 
78] although such therapy is a common feature in the ICU, reportedly as high as 25-30% [6, 59]. Our 
results are in accord with these findings as despite using international guidelines based local protocols, 
and regular consultation with clinical microbiologists and infectious disease specialist for years, 23% of 
patients with proven infection received inappropriate antibiotics initially. The main reason for this high 
rate of inadequacy reported worldwide may be due to the fact that reliable clinical and biochemical 
signs of bacterial infections are lacking, and the microbiological proof becomes available well after the 
antibiotic therapy was commenced. This is also supported by the fact, that apart from the respiratory 
origin of infection, we could not identify significant differences between the A-, and IA-groups neither 
in etiology, origin of infection (community or nosocomial) nor in demographics. Once inappropriate 
antimicrobials are initiated, it often takes days (until organism isolation and sensitivities are produced) 
to correct them. In our study 23% of patients received inappropriate antimicrobials. This high incidence 
may be due to the lack of fast and reliable diagnostic tests for bacterial infections, and to the subsequent 
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delay in microbiological results. Earlier recognition of potential inappropriate microbial therapy may 
allow an opportunity to substantially improve outcome. 
To our knowledge, this is the first study to show that the early kinetics of PCT measured within the 
first 24 hours may help clinicians to evaluate the appropriateness of empirical antimicrobial therapy in 
critically ill patients. The rationale for measuring successive PCT levels within this timeframe came 
from the assumption that by giving appropriate antibiotics this may slow the inflammatory response 
within hours, and that this could be detected by serial measurements of PCT. 
In this study, although PCT continued to increase after the initiation of empirical antimicrobial 
treatment during the first 16 hours in both the A-, and IA-groups, in the A-group there was a significant 
PCT decrease during the next eight hours (t24), while in the IA-group PCT continued to increase and 
reached a significantly higher level by t24, and remained higher the next day compared to the A-group. 
A PCT increase of ≥69.2% during the first 16 hours or a PCT increase ≥73.5% during the first 24 hours 
were the best cut off values to indicate inappropriate antimicrobial treatment. It is known that PCT 
increases within hours after an infectious insult and levels halve daily once the infection is controlled by 
the host immune system and/or by appropriate antibiotic therapy [79]. This feature explains the 
significant difference found in the PCT kinetics between the A-, and IA-groups during the first 24 
hours. 
It is also important to note that despite the inappropriate treatment after day one PCT decreased in 
both groups, although PCT levels remained significantly higher in the IA-group. This is in line with the 
results from Charles et al. [59], who measured PCT during the first 4 days of treatment in 180 patients 
with documented sepsis on a medical ICU, and PCT time course was analysed according to the 
appropriateness of the first-line empirical antibiotic therapy. They found that PCT decreased from day 2 
to day 3 in both, the appropriate and inappropriate groups, but the decrease was significantly greater in 
the appropriate group. This can be explained by the finding that adequate supportive therapy on its own 
may attenuate the inflammatory response [80]. Furthermore, monocytes become exhausted after a 
certain period of time, also affecting PCT production [81, 82]. 
The clinical importance of these findings is emphasised by the significant difference in hospital 
mortality in our study: 35% in the A-group and 66% in the IA-group. In the study by Charles et al., a PCT 
decrease from day 2 to day 3 less than 30% was associated with death, and a delta PCT day 2 – day 3 was 
also found to be an independent predictor of mortality [59]. This gives further support to previous findings 
that early adequate antibiotic therapy has a pivotal role on survival [5, 78]. 
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It is also true by the study by Charles et al. [59], they observed a signal of lower PCT levels on day 
2 in the appropriate group, but the difference wasn’t significant. This may be due to the fact that in their 
study PCT was measured retrospectively, therefore the time elapsed between the PCT measurements 
and the antibiotic therapy was uncontrolled, unlike this study where investigating PCT kinetics as 
precisely as possible during the first 24 hours was a particular aim. 
It may be of significance that the grouping was based on the initial antibiotic therapy, hence no 
patients were “crossed over” from the inappropriate to the appropriate group. However, from the 33 
patients in the IA-group, antibiotics were changed on day 2 or day 3 in 18 cases. We analyzed and 
compared PCT kinetics in patients in whom we changed (n=18) as compared to patients in whom we 
did not change (n=15) antibiotics over the study period but found no significant differences (data not 
shown). 
Translating the results of the current study into clinical practice means that measuring PCT on 
commencement of antimicrobials (t0) and then at 16 and 24 hours, by evaluating the percentage change 
rather than the absolute values the clinicians may have some additional early help when there is nothing 
else to follow but the clinical picture. In those cases where there is a “large” increase within the first 16-
24 hours (≥69.2-73.5%), may indicate inappropriate antimicrobial therapy, while a lower grade increase 
or a decreasing tendency after 16 hours would support appropriate antimicrobial therapy. Within the 
first 16 hours, followed by further increase after that indicates that antibiotic therapy may need 
adjusting, such as reevaluating dosage, escalating or changing treatment; in the case of a lower grade 
increase till 16 hours followed by a decreasing tendency may mean adequate empirical antibiotic 
therapy. However, it is important to note, that one should never treat one single parameter, and PCT 
also has to be dealt with in the context of the full clinical picture and other biochemical and 
microbiological results. The clinical importance of our findings is emphasized by the significant 
difference in hospital mortality between the A-group and the IA-group (37% versus 61%). 
Another important finding of the current study is that CRP did not differentiate between the 
appropriate and inappropriate groups within the first 48 hours while changes in the PCT levels gave a 
significant signal within the first 24 hours regarding the adequacy of empirical antibiotic therapy. This 
is in accordance with previously published data indicating that CRP is a “slow” marker and not as 
reliable as PCT in the critically ill [83, 84]. The same holds true for body temperature, which as with 
other studies, highlights that its use for guiding antimicrobial therapy is questionable [35]. 
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7.3 PCT kinetics in surgical as compared to medical patients 
Our results also support that PCT is several times higher in surgical compared to medical patients 
in septic shock despite the similar clinical manifestation and severity of the clinical picture [53], but we 
also found that early kinetics were similar to that found in the whole sample. Our data also suggest that 
percentage changes of PCT may be a better, universally applicable approach for monitoring treatment 
progress rather than absolute values.  
A recently published randomized, interventional study on antibiotic-escalation based on daily PCT 
measurements by Jensen et al., found that PCT-guided antimicrobial escalation did not improve 
survival (31.5 % vs. 32 %) and led to organ-related harm, such as increased rate of mechanical 
ventilation, worsening glomerular filtration rate and prolonged length of stay (by 1 day) in the intensive 
care unit [51]. In a subsequent single-centre, prospective study the authors tested the usefulness of PCT 
for the reduction of antibiotic consumption in a multidisciplinary (surgical and medical) intensive care 
unit. They concluded that PCT measurements for the initiation of antimicrobials did not appear to be 
helpful in a strategy aiming at decreasing the antibiotic consumption in intensive care unit patients [10]. 
The authors of the PASS study and also in the study by Layios et al., used the same PCT algorithm, as 
first reported by Müller and co-workers [50]. However, in both studies the threshold for intervention 
was a PCT of >1 ng/ml. As 40% of the patients in both trials were surgical, in whom this threshold for 
intervention may be too low, one cannot exclude that these patients may have had received antibiotics 
unnecessarily. This overuse of antibiotics could be one of the reasons of the worse outcome in the PCT-
guided group in both studies. 
There is strong evidence that, due to direct cellular damage as in severe trauma, major surgery, and 
after ischemia-reperfusion, also known as damage associated molecular patterns (DAMP), hence 
unspecific elevations of PCT levels can typically be seen in the absence of a bacterial infection [84, 85] 
that there is an inflammatory mediator release very similar to that following an infectious insult. In the 
case of infection, a similar inflammatory response, often referred to as pathogen associated molecular 
pattern (PAMP), will also be triggered [86]. Therefore, unspecific elevations in PCT levels can 
typically be seen in the absence of a bacterial infection [84, 85]. Theoretically, in surgical patients with 
sepsis DAMP and PAMP takes place at the same time leading to a pronounced inflammatory response, 
whilst in medical patients PAMP may occur on its own, resulting in a less extensive inflammatory 
response [60].This theory has nicely been confirmed by Clec’h et al., that the same severity of SIRS, 
sepsis and septic shock is accompanied by several times higher PCT levels in the surgical as compared 
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to the medical patients. Therefore, using a cut-off value of PCT of 1 ng/ml in a surgical population will 
inevitably give false positive results and lead to unnecessary overuse of antibiotics. This is what may 
have happened in the above mentioned two negative studies, which explains their results at least in part. 
This feature is the reason why the same absolute values of PCT may mean completely different 
information in a medical compared to a surgical patient, but as shown in our results, kinetics follow a 
uniform pattern. 
Our results in the EProK study are in accord with the Clec’h et al., study and also add further 
important information. We found that although the absolute values of PCT showed substantial 
differences, with being higher in the surgical group as compared to the medical patients, but we also 
found similar kinetics in both patient populations. This indicates, that using the same threshold of PCT 
for surgical and medical patients should not be recommended, but following the kinetics, i.e.: the 
percentage changes of PCT over time may be a better monitoring tool for diagnosing new onset 
infection and monitoring treatment progress. It is also important to note, that PCT reached its peak 
value at t8 in the medical group receiving appropriate antibiotics (Am-group), whilst in the As-group the 
peak was reached 8 hours later, at t16. This suggests, that in medical patients PCT may indicate efficacy 
of therapy several hours earlier as compared to surgical patients. However, due to the small sample size 
of these subgroups we cannot give the exact percentage changes of PCT within 8 (medical) and 16 
(surgical) hours to predict appropriate antibiotic treatment. It is something what has to be investigated 
further in the future. 
This phenomen could be seen in our spin off study as well what also explains why PCT levels were 
elevated in our surgical patient population without proven infections, with median values of around 3.5 
(NI-group) and 3.8 (I-group) ng/ml at t-1. The corresponding PCT values in medical patients were 
substantially lower (0.26 and 0.89 ng/ml, respectively). Although levels were higher in the I-group at t-
1, but this difference did not reach statistical significance, while there was a several fold increase in the 
I-group in both medical and surgical patients with no change in kinetics in the NI-groups. 
Our studies provide further evidence that changes or kinetics of PCT may be superior to absolute 
values. 
7.4 Limitations: important to note 
The most important limitation for us during the analysis of the results was the lack of gold standard 
for diagnosing infection. Although we attempted to reduce the potential error in judgment, by allocating 
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patients into each group by two independent experts blinded for PCT-kinetics in a post hoc fashion 
taking all clinical and microbiology data into account, one cannot exclude that mistakes may have still 
appeared in the process. It remains uncertain, what was the reason of measuring PCT values on the 
previous day before starting empiric antibiotic therapy in more than 50% out of the 209 patients of the 
EProK study. Therefore, some selection bias cannot be excluded. Furthermore, the power analysis 
sample size could have been larger to detect a stronger signal, so a multicenter design would have been 
better especially so to draw firm conclusions regarding the medical, surgical subgroups, although the 
trend in our results is certainly promising. It may also be important to note the uneven proportion of 
patients in the appropriate and inappropriate groups (75% vs. 25%), which is a general limitation of 
every study in this field, which may also have affected our results. The median day of inclusion into the 
study from ICU admission was 1 day, indicating, that 50% of patients had PCT measurements on 
ward/Accident and Emergency unit, before admission. However, this may also reinforces the 
importance of measuring PCT values consecutively. Finally, the clinical impact of our findings will 
have to be tested in a prospective randomized trial in order to see whether tailoring empirical 
antimicrobial therapy to PCT-kinetics, has any effect on outcome. 
7.5 Conclusion 
In the ERroK study PCT kinetics within the first 24 hours after commencing empirical 
antimicrobial therapy showed a significant increase in patients in whom therapy proved to be 
inappropriate, while in the appropriate group, after a brief increase at 16 hours, there was a significant 
decrease by 24 hours (Figure 12). Applying this approach may be helpful in quickly tailoring 
antimicrobial therapy for the patient’s specific needs. However, the clinical relevance of this ”PCT 
kinetics-guided approach” should be confirmed in a prospective randomized fashion. 
The main finding of the spin off observational study was that an increase in PCT levels from the 
day before (t
-1) to the day when infection was suspected (t0) predicted infection, while in patients with 
no proven infection PCT remained unchanged. Based on the data presented spot PCT may not be 
adequate to differentiate infection from non-infectious inflammatory response. Furthermore, 
conventional indicators of infection such as white cell count, body temperature and CRP have limited 
use to predict infection. The clinical implication of these results is, that daily PCT measurements in 
patients with high risk of infection would give the opportunity to evaluate PCT kinetics, which may 
improve our diagnostic accuracy and rationalize antibiotic therapy on the ICU. 
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Figure 12 Procalcitonin kinetics in the first 24 hours in appropriate (blue arrows) and 
inappropriate (red arrows) empiric antibiotic therapy groups. The draft version of 
Figure 5 A. 
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8 PCT-ASSISTED ANTIBIOTIC THERAPY 
 
There are three fundamental questions to be answered during our ward rounds when treating 
patients with suspected or proven infections on the ICU: 1) is there infection, in other words should we 
start empirical antibiotic therapy; 2) is the commenced antibiotic effective; and finally 3) when should 
we stop antibiotic treatment? 
8.1 Diagnosing infection and starting antibiotics 
The role of PCT in diagnosing infection has been discussed in details earlier. Several studies 
investigated the effects of PCT-guided antibiotic therapy on patient outcomes. In a landmark study by 
Christ-Crain et al., antibiotic exposure was reduced by 50% (44% versus 83%) in patients admitted to 
emergency wards with acute respiratory complaints, when antibiotic therapy was guided by admission 
PCT levels, as compared to conventional signs of infection only [8]. Two subsequent multicenter trials 
also found a decrease in antibiotic exposure in patients treated on the ICU with infections [9, 71]. The 
possible reasons why other studies [10, 12], could not find positive results were discussed earlier. 
Patients treated on the ICU for a longer period of time may develop an imbalance between pro-, 
and anti-inflammatory forces in a way that the latter becomes prominent. These patients will become 
immunoparalyzed, making them prone to a series of recurrent infections. Detecting infection in these 
patients may prove even more difficult. In a recent study by Rau et al. [87], it was found that in patients 
with secondary peritonitis, PCT levels increased and indicated infection, but the peak values decreased 
significantly by each new insult. This was also supported by Charles et al. [59]. They found that during 
the first infectious insult the PCT mean was 55 ng/ml, but during the second infectious insult despite the 
same clinical gravity it was several fold less, 6.4 ng/ml. These data indicate that as we go along in time, 
patients become immunoparalized on the ICU and lower levels of PCT should be taken just as seriously 
as high levels at the early course of the disease. Furthermore, this provides further evidence, that PCT 
will respond to the same insult differently during the course of the disease, hence should be interpreted 
with special attention. 
To put a bit of that into clinical practice, two very common scenarios will be discussed, which are 
summarized in two decision trees (Figure 13 and 14). Figure 13 shows how PCT can help in decision 
making when infection is suspected. If the patient is hemodynamically unstable and infection is likely, 
by definition he/she has septic shock or at least one cannot exclude it, hence antibiotic therapy 
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shouldn’t be delayed but has to be commenced immediately, regardless of the PCT or any biomarker 
value [4]. However, if the patient is stable hemodynamically, and PCT is “low” or decreasing (based on 
the problems with absolute PCT values, discussed in detail above, we deliberately avoid giving exact 
numbers), then we can wait, observe the patient and reassess later (Figure 13) [8]. 
 
 
Figure 13 Guideline for staring empiric antibiotic therapy 
 
The next scenario demonstrates the reevaluation of the situation when microbiological data 
becomes available, which usually takes place 2-3 days after specimen were sent off to the laboratory 
and antibiotics had been commenced (Figure 14). There are several issues to consider. Whether or not 
there was clinical improvement, combining it with both the microbiological and PCT results, this 
multimodal approach can assist us whether to continue, reconsider or change antibiotics and/or reassess 
organ support and most importantly, to stop antibiotics even on day 3 if they are considered 
unnecessary. (For more explanation see Figure 14.) 
This multimodal evaluation could be called the MET-concept: Measure, Evaluating and Treat, 
which may help to individualize suspected infection management in the early course of sepsis on the 
ICU. 
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8.2 Evaluating antibiotic appropriateness 
Once we decided to commence empirical antibiotic therapy, it is of utmost importance to confirm 
the appropriateness, type and dose, or change treatment if needed as soon as possible, because antibiotic 
therapy is a double edged sword. On the one hand we have some evidence that in septic shock every 
hour delay in starting adequate antibiotic therapy could have serious effect on survival [4]. On the other 
hand, unnecessary overuse of antibiotics can also cause harm, such as: increased bacterial resistance, 
the occurrence of multi-resistant strains, invasive fungal infections, side effects of the drug itself, and 
increased costs [68]. International guidelines based local protocols and antibiotic stewardship may help 
in choosing the right medication with the best possible chance. Unfortunately, no matter how hard we 
try, it seems that inappropriate empirical antibiotic therapy is a common feature on the ICU and in the 
hospital in general, and it can be as high as 25-30% [6, 59]. The gold standard for proving 
appropriateness of antibiotic therapy is the microbiological confirmation of the bacteria and its 
susceptibility. However, these results may come far too late, in reality days after the specimen had been 
sent, but treatment cannot be delayed. At present there is very little to help the clinicians at the early 
stage of patient care to confirm appropriate antibiotic treatment. In a recent pilot study we measured 
PCT before initiating antibiotics (t0), and then 8 hourly (t8, t16, t24) after commencing empirical 
antibiotic therapy, and found that there was a significant difference in the kinetics between patients 
receiving appropriate as compared to those getting inappropriate antibiotic therapy. Receiver Operating 
Characteristic analysis revealed that a PCT elevation ≥69% within the first 16 hours (i.e. from t0-t16) 
had an area under curve (AUC) for predicting inappropriate antibiotic treatment of 0.73 [95%CI: 0.63-
0.83], p<0.001; from t0-t24 a ≥73,5% increase had an AUC of 0.86 [0.77-0.94], p<0.001. These data 
suggest that early response of PCT within the first 24 hours of commencing empirical antibiotics in 
critically ill patients may help the clinician to evaluate the appropriateness of therapy, a concept which 
certainly will have to be tested in the future. Nevertheless, hospital mortality was 37% in the 
appropriate and 61% in the inappropriate group (p=0.017), which provides further evidence that 
choosing inappropriate antibiotic therapy seriously affects survival. 
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Figure 14 Multimodal reassessment of antibiotic therapy on day 2-3 
ABs - antibiotics; Micro - microbiology; PCT - procalcitonin (↑ - increasing; ↓ - decreasing 
levels); Cont - continue; Infect -infectologist. 
Once empirical antibiotics were commenced, a multimodal reassessment of the situation, 
once microbiological data is available usually on day 2 or 3, is strongly recommended.  
No clinical improvement: Despite no clinical improvement a decrease in PCT (A-1) still 
may indicate that the infection is under control, but the patient needs more time to gain 
benefit from treatment. Therefore, ABs should be continued. On the contrary (A-2), if PCT 
is not decreasing or even increasing, these can be important signs that infection is not 
under control, hence source of infection and antibiotics (type, dose) should be reassessed. 
If antibiotics are appropriate, depending on PCT changes ABs should either be continued 
(B-1) or other sources of infection should be looked for (B-2). In case of inappropriate ABs 
and no clinical improvement, regardless of the PCT, therapy should be changed (C). 
Clinical improvement: If there is no proof of infection (micro: negative), based on PCT 
changes (↓ or ↑) infection may be excluded and ABs stopped (A-1), or continued (A-2). 
Similar algorithms can be applied if ABs are appropriate (B-1,2). If ABs are inappropriate 
and PCT decreases, then one may consider the microbiology as false positive and stop ABs 
(C-1), because it is highly unlikely that there is clinical improvement and decreasing PCT 
if an infection is not under control due to inappropriate ABs. This scenario happens when 
there are pathogens (colonization for example), but no infection. Finally, in case of 
inappropriate ABs and unfavourable PCT changes (C-2), consultation with infectologists 
and microbiologists is recommended. 
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8.3 Stopping antibiotic therapy 
Procalcitonin, mainly due to its favourable kinetic profile can potentially be a useful biomarker for 
also the cessation of antibiotic treatment [70]. In the PRORATA study [9], PCT-guided antibiotic 
management was tested in an ICU population. Similarly to the Christ-Crain study [8], antibiotics were 
encouraged in case of elevated PCT levels, and discouraged when levels were low. The novelty of this 
trial was, that investigators were encouraged to discontinue antibiotics when PCT concentration was 
less than 80% of the peak value or when absolute concentration of less than 0.5 ng/ml was reached. 
This approach shortened antibiotic exposure by 23%, and by almost 3 days in the PCT-group as 
compared to conventionally treated patients. Putting these results into clinical practice is also included 
in Figure 15. 
 
Figure 15 Guideline for stopping antibiotic by the PRORATA study 
 
However, it is very important to acknowledge that patients in the PCT-group also received 
antibiotics for a shorter period of time as recommended by guidelines and their local protocols. Despite 
the significantly shorter antibiotic therapy, they were unable to show any difference in outcome 
between the groups, in other words patients did not suffer harm from not receiving antibiotics for the 
length of time recommended by guidelines. In two other studies on high risk surgical patients with 
suspected infection, PCT-guided therapy during the postoperative period in the ICU also resulted in 
significant reduction of antibiotic therapy and length of intensive care stay [72, 73]. 
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In a recent large multicenter study by Shehabi et al., the authors could not find significant 
differences between the PCT-guided as compared to the conventional groups, although patients 
received a median of 2 days less (9 vs 11 day) antibiotics, which in fact was the main outcome measure 
[12]. However, as it was clearly stated by the authors, the study was powered for a very ambitious 25% 
reduction in the length of antibiotic treatment based on an estimated 9 days long antibiotic therapy, 
which in fact translated after the final analysis into an almost 4 days reduction in the study arm, with 11 
antibiotic treatment days being the baseline in the control arm. 
8.4 Final conclusion 
In this deadly battle of fighting the burden of serious infections on the ICU, we often keep missing 
the point. Although sepsis exists, just like critical illness, but precisely defining it is probably 
impossible due its diversity in etiology, pathomechanism and clinical manifestation. Therefore, 
interpreting the results of sepsis studies is a daunting task. Procalcitonin is definitely one of the most 
reliable inflammatory markers in the critically ill to date, and there is also convincing evidence that its 
use to guide antibiotic therapy can rationalize starting, escalating and stopping antibiotic therapy. 
Furthermore, when the concept applied highlighted in this thesis, PCT may also become cost effective, 
by not starting at all, or stopping antibiotic therapy early. However, starting or stopping antibiotic 
treatment is more complex than just treating one single figure or even the kinetics of PCT values. A 
multimodal, individualized concept, consisting of a) recognizing organ dysfunction, b) identifying the 
possible source, c) following the clinical picture and d) taking PCT and PCT-kinetics into account, is 
necessary to make the most out of your PCT and to do the best of your patients in your everyday 
practice. And yes, it requires a well-trained, thinking physician, who dials in all information, “seasons” 
it with his/her experience and then makes a decision. And even if this decision turns out to be a wrong 
one retrospectively, it doesn’t matter. Because, these “wrong decisions” are what we call later as: 
“experience”. 
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KEY MESSAGE OF THE EPROK STUDY 
 
•   Early PCT kinetics within the first 24 hours after commencing empirical antimicrobials are 
different in patients receiving appropriate as compared to patients on inappropriate 
antimicrobial therapy. 
•   In case of appropriate therapy PCT peaks around 16 hours after commencing empirical 
antimicrobials and by 24 hours it already shows a decline. 
•  In patients on inappropriate antimicrobials PCT levels show a continuous increase within the 
first 24 hours during empirical antimicrobial therapy. 
•  Although absolute values showed several fold difference in medical as compared to surgical 
patients with suspected infection, but kinetics in those receiving appropriate as compared to 
those who received inappropriate antimicrobials were similar to that of reported in the whole 
sample. 
 
KEY MESSAGE OF THE SPIN OFF STUDY 
 
•  Kinetics of procalcitonin values based on daily measurement are superior to absolute values 
only in diagnosing infection on the ICU. 
•  Absolute values of procalcitonin may be of limited use in diagnosing infection on the ICU. 
•  Both absolute values and kinetics of C-reactive protein and body temperature are poor 
indicators of infection on the ICU. 
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